Vivek Subbiah: It’s a wrap for the 2024 AACR Industry Roundtable

Vivek Subbiah shared on LinkedIn:

“What an amazing meeting! It’s a wrap for the 2024 AACR Industry Roundtable, Philadelphia, Oct 8th and 9th.

Two full days of thought-provoking discussions spearheaded by AACR President Elect Dr. Lillian Siu on role of AI in oncology, tracking and treating early cancers, advancing diversity in clinical trials, and the impact of patient advocates on cancer research

Thanks to all the multi-stakeholder panelists from academia, FDA, industry, patient advocacy, community and AACR colleagues for insightful discussions and to AACR for their commitment to advancing our mission to eradicate cancer.”

More posts featuring Vivek Subbiah on oncodaily.com

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.